Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Summary
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Description
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source